Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 17, 2015, Pages 5425-5430

  Shen, Liangliang ^a,b,c   O'Shea, John M ^b,c   Kaadige, Mohan R ^b,c   Cunha, Stéphanie ^b,c   Wilde, Blake R ^b,c   Cohen, Adam L ^b,c   Welm, Alana L ^b,c,d   Ayer, Donald E ^b,c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Glycolysis; MondoA; Myc; Thioredoxin interacting protein; Triple negative breast cancer

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; MESSENGER RNA; MYC PROTEIN; PROTEIN P53; THIOREDOXIN INTERACTING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MONDOA; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; CARRIER PROTEIN; GLUCOSE; MONDOA PROTEIN, HUMAN; MYC PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TXNIP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL METABOLISM; CONTROLLED STUDY; GENE MUTATION; GENE REPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOLYSIS; HUMAN; HUMAN CELL; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CELL SURVIVAL; FEMALE; GENETICS; METABOLISM; MUTATION; NUCLEAR REPROGRAMMING; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CELLULAR REPROGRAMMING; FEMALE; GLUCOSE; GLYCOLYSIS; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84928544717     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1501555112     Document Type: Article

References (45)

1. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938-1948.
2. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7(1):11-20.
3. Palaskas N, et al. (2011) 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res 71(15):5164-5174.
4. Timmerman LA, et al. (2013) Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24(4):450-465.
5. Alles MC, et al. (2009) Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS ONE 4(3):e4710.
6. Chandriani S, et al. (2009) A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS ONE 4(8):e6693.
7. Dang CV (2012) MYC on the path to cancer. Cell 149(1):22-35.
8. Meyer N, Penn LZ (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8(12):976-990.
9. Ward PS, Thompson CB (2012) Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 21(3):297-308.
10. Morrish F, Isern N, Sadilek M, Jeffrey M, Hockenbery DM (2009) c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 28(27):2485-2491.
11. O'Shea JM, Ayer DE (2013) Coordination of nutrient availability and utilization by MAX- and MLX-centered transcription networks. Cold Spring Harb Perspect Med 3(9):241-256.
12. Stoltzman CA, et al. (2008) Glucose sensing by MondoA:Mlx complexes: A role for hexokinases and direct regulation of thioredoxin-interacting protein expression. Proc Natl Acad Sci USA 105(19):6912-6917.
13. Kaadige MR, Looper RE, Kamalanaadhan S, Ayer DE (2009) Glutamine-dependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity. Proc Natl Acad Sci USA 106(35):14878-14883.
14. Hui ST, et al. (2008) Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci USA 105(10):3921-3926.
15. Wu N, et al. (2013) AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell 49(6):1167-1175.
16. Chen JL, et al. (2010) Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet 6(9):e1001093.
17. Ikarashi M, et al. (2002) Vitamin D3 up-regulated protein 1 (VDUP1) expression in gastrointestinal cancer and its relation to stage of disease. Anticancer Res 22(6C):4045-4048.
18. Sheth SS, et al. (2006) Hepatocellular carcinoma in Txnip-deficient mice. Oncogene 25(25):3528-3536.
19. Shin D, et al. (2008) VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway. Biochim Biophys Acta 1783(5):838-848.
20. Gross MI, et al. (2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 13(4):890-901.
21. DeRose YS, et al. (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17(11):1514-1520.
22. Walz S, et al. (2014) Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 511(7510):483-487.
23. Elgort MG, O'Shea JM, Jiang Y, Ayer DE (2010) Transcriptional and translational downregulation of Thioredoxin Interacting Protein is required for metabolic reprogramming during G1. Genes Cancer 1(9):893-907.
24. van de Vijver MJ, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999-2009.
25. Cadenas C, et al. (2010) Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res 12(3):R44.
26. Cunha S, et al. (2014) The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. Cell Reports 6(1):141-154.
27. Turner N, et al. (2013) Targeting triple negative breast cancer: Is p53 the answer? Cancer Treat Rev 39(5):541-550.
28. Carroll PA, et al. (2015) Deregulated Myc Requires MondoA/Mlx for Metabolic Reprogramming and Tumorigenesis. Cancer Cell 27(2):271-285.
29. Yu FX, Luo Y (2009) Tandem ChoRE and CCAAT motifs and associated factors regulate Txnip expression in response to glucose or adenosine-containing molecules. PLoS ONE 4(12):e8397.
30. Stoltzman CA, Kaadige MR, Peterson CW, Ayer DE (2011) MondoA senses non-glucose sugars: Regulation of thioredoxin-interacting protein (TXNIP) and the hexose transport curb. J Biol Chem 286(44):38027-38034.
31. Herkert B, Eilers M (2010) Transcriptional repression: The dark side of myc. Genes Cancer 1(6):580-586.
32. Billin AN, Eilers AL, Coulter KL, Logan JS, Ayer DE (2000) MondoA, a novel basic helix-loop-helix-leucine zipper transcriptional activator that constitutes a positive branch of a max-like network. Mol Cell Biol 20(23):8845-8854.
33. Cole MD, Nikiforov MA (2006) Transcriptional activation by the Myc oncoprotein. Curr Top Microbiol Immunol 302:33-50.
34. Goldberg SF, et al. (2003) Melanoma metastasis suppression by chromosome 6: Evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res 63(2):432-440.
35. Masaki S, Masutani H, Yoshihara E, Yodoi J (2012) Deficiency of thioredoxin binding protein-2 (TBP-2) enhances TGF-β signaling and promotes epithelial to mesenchymal transition. PLoS ONE 7(6):e39900.
36. Gatza ML, et al. (2010) A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA 107(15):6994-6999.
37. Horiuchi D, et al. (2012) MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 209(4):679-696.
38. Peterson CW, Stoltzman CA, Sighinolfi MP, Han KS, Ayer DE (2010) Glucose controls nuclear accumulation, promoter binding, and transcriptional activity of the MondoA-Mlx heterodimer. Mol Cell Biol 30(12):2887-2895.
39. Chutkow WA, Patwari P, Yoshioka J, Lee RT (2008) Thioredoxin-interacting protein (Txnip) is a critical regulator of hepatic glucose production. J Biol Chem 283(4):2397-2406.
40. Billin AN, Eilers AL, Queva C, Ayer DE (1999) Mlx, a novel Max-like BHLHZip protein that interacts with the Max network of transcription factors. J Biol Chem 274(51):36344-36350.
41. Curtis C, et al.; METABRIC Group (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346-352.
42. Bild AH, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439(7074):353-357.
43. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30(1):207-210.
44. Heiser LM, et al. (2012) Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci USA 109(8):2724-2729.
45. Piccolo SR, Withers MR, Francis OE, Bild AH, Johnson WE (2013) Multiplatform single-sample estimates of transcriptional activation. Proc Natl Acad Sci USA 110(44):17778-17783.